Skip to content

Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapy

Oct 2026 · Cancer · Vol 132 · 0 citations · 35 references
Medicine

TL;DR

This study evaluated outcomes with 1L GemCis versus GemCis + ICI in ctDNA‐identified IDH1‐mutant aCCA in ctDNA‐identified IDH1‐mutant aCCA.

Abstract

Comprehensive genomic profiling (CGP) is recommended for advanced cholangiocarcinoma (aCCA). Circulating tumor DNA (ctDNA) testing provides a noninvasive alternative with concordance to tissue. Standard first‐line (1L) therapy is gemcitabine and cisplatin (GemCis) with or without immune checkpoint inhibitors (ICIs). Data suggest that patients with isocitrate dehydrogenase 1 (IDH1) mutations may derive less benefit from ICIs. This study evaluated outcomes with 1L GemCis versus GemCis + ICI in ctDNA‐identified IDH1‐mutant (IDH1+) aCCA.

View source

Similar papers

Open access Sep 2026

Dynamic Changes of ctDNA‐Based MRD and Genomic Mutations Predict Prognosis in ESCC Treated With Definitive Radiotherapy

ABSTRACT This study characterized the genomic profile of esophageal squamous cell carcinoma (ESCC) via circulating tumor DNA (ctDNA) to identify predictive biomarkers for efficacy of definitive radiotherapy combined with systemic therapy. In this prospective cohort of 40 ESCC patients, 7 tumor tissues and 71 serial pla...

Shu-Tang Liu, Qi Wang, Chun Han et al. · 0 citations
Open access Oct 2026

EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study

Follicular lymphoma is the most common indolent lymphoma and next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D, CREBBP, and EZH2 ).

C. Martínez-Laperche, Pilar Lancho-Lavilla, Antonio Gutiérrez et al. · 0 citations
Open access Oct 2026

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Patients with chemotherapy‐ and androgen receptor pathway inhibitor (ARPI)‐naïve metastatic castration‐resistant prostate cancer (mCRPC) have generally shown worse overall survival (OS) with abiraterone versus enzalutamide in claims database studies. Given limitations of claims data, analysis using detailed electronic...

D. George, J. Ivanova, M. Touya et al. · 0 citations
Open access Sep 2026

Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy

It is suggested that baseline and early on-treatment multigene ctDNA carries prognostic information in advanced PDAC, although superiority over KRAS or CA19-9 was not established.

Gi-Ye-On Lee, J. W. Chun, Dong-eun Lee et al. · 0 citations
Review Open access Nov 2026

Predictors of Benefit from Immune Checkpoint Inhibitors in Urothelial Carcinoma of the Bladder: The Limits of PD-L1 and the Rise of Circulating Tumor DNA-Guided Adjuvant Therapy.

Immune checkpoint inhibitors (ICIs) are established across the treatment continuum of urothelial carcinoma of the bladder, yet most patients derive no durable benefit. This narrative review appraises candidate predictors of ICI benefit in bladder urothelial carcinoma, distinguishing prognostic from predictive biomarker...

D. Novacescu, Mihael Musta, Radu Căprariu et al. · 0 citations
Sep 2026

Abstract B045: Plasma cfDNA 5-hydroxymethylcytosine signatures associate with treatment response and molecular subtype in BRCA -mutant pancreatic cancer

Biomarkers that predict and monitor response to platinum-based chemotherapy and PARP-inhibitor (PARPi) therapy remain an unmet need in BRCA-positive pancreatic ductal adenocarcinoma (PDAC). Furthermore, blood-based assays to classify tumor expression subtypes are limited. Cell-free DNA (cfDNA) 5-hydroxymethylcyto...

Ceyda Çoruh, M. Raitses-Gurevich, Y. Ning et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.